Oxaliplatin is the most commonly used drug to treat colorectal cancer (CRC), but patients often develop resistance to it. So, researchers conducted a study to determine the effect of CBD in overcoming oxaliplatin resistance in CRC cells. They found that elevated NOS3 phosphorylation is an essential part of the development of oxaliplatin resistance, and CBD successfully decreased NOS3 phosphorylation. This effect resulted in cells overcoming oxaliplatin resistance, which suggests that CBD could be a new strategy to treat colorectal cancer.
View this review (yellow link) or download:
To explore related information, click the keywords below: